Sarilumab Market

The Sarilumab market is projected to grow at a CAGR of 6.6% from 2025 to 2035, driven by rising prevalence of autoimmune diseases, increasing adoption of interleukin-6 (IL-6) inhibitors for rheumatoid arthritis (RA) management, and expanding indications for inflammatory and immune-mediated conditions. Sarilumab is a fully human monoclonal antibody that targets the interleukin-6 receptor (IL-6R), inhibiting the pro-inflammatory signaling pathway associated with RA and other chronic inflammatory disorders.

Marketed under the brand name Kevzara, Sarilumab is FDA- and EMA-approved for the treatment of moderate-to-severe rheumatoid arthritis in adults who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). Administered via subcutaneous injection, Sarilumab improves symptoms, halts disease progression, and enhances physical function. During the COVID-19 pandemic, Sarilumab was also investigated for its potential in managing severe cytokine release syndrome, which has further highlighted its anti-inflammatory potential. Ongoing clinical trials are exploring its use in other IL-6–driven disorders such as giant cell arteritis and systemic lupus erythematosus.

North America currently leads the Sarilumab market, supported by strong biologics uptake, high RA prevalence, favorable reimbursement policies, and extensive prescriber familiarity with IL-6 inhibitors. Europe follows with robust demand, particularly in Germany, France, and the UK, driven by national rheumatology treatment protocols and biosimilar penetration. The Asia-Pacific region is poised for the fastest growth, attributed to increasing diagnosis rates of autoimmune conditions, greater biologic drug accessibility, and rising healthcare spending in countries like China, Japan, and South Korea. Latin America and the Middle East & Africa exhibit steady growth, fueled by improving biologics access and rising awareness of advanced RA therapies.